
Travere Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results
NewsSAN DIEGO, March 01, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its fourth quarter and full year 2020 financial results and provided a corporate update.
Read the full press release >







Travere Therapeutics Recognizes Rare Disease Day 2021 and the Importance of Working Together to Innovate and Address Healthcare Disparities in Rare Disease
NewsSAN DIEGO, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) will join the National Organization for Rare Disorders (NORD), the European Organisation for Rare Diseases (EURORDIS), EveryLife Foundation for Rare Diseases, Global Genes, and rare disease advocates and patients worldwide in recognizing February 28 as Rare Disease Day 2021.
Read the full press release >

Rare Disease Diversity Coalition Formed To End Racial Disparities In Rare Disease Diagnosis, Research And Treatment
News

RARE-X Announces Patient Community Data Collection, Sharing, and Platform Enhancements with Support from Travere
News







Travere Therapeutics Announces European Commission Has Granted Orphan Designation to Sparsentan for the Treatment of IgA Nephropathy
NewsSAN DIEGO, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the European Commission (EC) has granted orphan designation to sparsentan for the treatment of IgA nephropathy (IgAN), a rare kidney disorder and a leading cause of end-stage kidney disease (ESKD).
Read the full press release >

Rare Disease Institute Provides Innovative Digital Solutions amidst Pandemic with Support from Travere
News







Travere Therapeutics Announces Achievement of Interim Proteinuria Endpoint in the Ongoing Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis
NewsSAN DIEGO, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company’s ongoing pivotal Phase 3 DUPLEX Study of sparsentan in focal segmental glomerulosclerosis (FSGS) achieved its pre-specified interim FSGS partial remission of proteinuria endpoint (FPRE) after 36 weeks of treatment.
Read the full press release >







Travere Therapeutics Announces Orphan Drug Designation for Sparsentan for the Treatment of IgA Nephropathy
NewsSAN DIEGO, Jan. 12, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to sparsentan for the treatment of IgA nephropathy (IgAN), a rare kidney disorder and a leading cause of end-stage kidney disease (ESKD).
Read the full press release >







Travere Therapeutics Provides Corporate Update and 2021 Outlook
News






